Skip to main content
. Author manuscript; available in PMC: 2024 Dec 16.
Published in final edited form as: Cancer Prev Res (Phila). 2014 Jan 17;7(4):378–387. doi: 10.1158/1940-6207.CAPR-13-0389

Table 3.

Adjuvant Hormone Therapy Use for Hormone Receptor Positive Postmenopausal Women with Early Stage Breast Cancer

In Women’s Health Initiative Cohort1 Kaiser Permanente Southern California2 In SEER Population by Survey3 Kaiser Permanente Northern California4
3,588 surveyed 2009–2010 22,850 in years 1996–2006 743 surveyed in years 2005–2007 13,753 studied in year 1996–2007
Use AI 33%, SERM 31%, mix 36% Use: SERM 38%, 19% AI, mix 16% Use: Endocrine 75% Not examined
17% none 24% none 10.8% none 30% none
33% of users became non-adherent 21% users became non-adherent 15.1% uses became non-adherent by year 4 Not examined
1

Livaudais J, LaCroix A, Chlebowski RT, et al. Use of and adherence to adjuvant hormonal therapy for breast cancer in the Women’s Health Initiative. Cancer Epidemiol Biomark Prev 2013;22(3):365–73.

2

Haque R, Ahmed SA, Fisher A, Avila CC, Shi J, Guo A, Craig Cheetham T, Schottinger JE. Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer. Cancer Med. 2012 Dec; 1(3):318–27.

3

Frease CR, Pini TM, Li y, et al. Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 2013;138:931–939.

4

Livaudais JC, Hershman DL, Habel L, et al. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat 2012; 131(2):607–617.